Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma.

[1]  P. Hari,et al.  Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Bay,et al.  Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study , 2021, Frontiers in Pharmacology.

[3]  M. Boccadoro,et al.  Dose/Schedule-Adjusted Rd-R vs Continuous Rd for elderly, intermediate-fit, newly diagnosed multiple myeloma patients. , 2021, Blood.

[4]  A. Palumbo,et al.  Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life , 2021, Blood Cancer Journal.

[5]  A. Lebioda,et al.  PRO143 Costs of Multiple Myeloma Patients Diagnosed with Peripheral Neuropathy in Germany , 2020 .

[6]  A. Jakubowiak,et al.  Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. , 2020, Blood.

[7]  M. Dimopoulos,et al.  Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd , 2020, Expert review of hematology.

[8]  P. Moreau,et al.  Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma , 2020, Leukemia & lymphoma.

[9]  H. Goldschmidt,et al.  Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma , 2020, Blood Cancer Journal.

[10]  A. Oriol,et al.  Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma. , 2019, Blood.

[11]  Xue Song,et al.  Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis , 2019, Therapeutic advances in hematology.

[12]  G. Morgan,et al.  Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial , 2019, The Lancet. Oncology.

[13]  D. Auclair,et al.  Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability? , 2018, Blood.

[14]  Shaji K. Kumar,et al.  Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  I. Abraham,et al.  Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. , 2017, Critical reviews in oncology/hematology.

[16]  B. Barlogie,et al.  Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial , 2017, The Lancet.

[17]  M. Petrucci,et al.  Managing treatment-related peripheral neuropathy in patients with multiple myeloma , 2016, Blood and lymphatic cancer : targets and therapy.

[18]  F. Mols,et al.  Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice , 2016, Supportive Care in Cancer.

[19]  K. Knopf,et al.  Real world impact of treatment-induced peripheral neuropathy (TIPN) on patient reported outcomes (PROs) in patients with multiple myeloma (MM) in the United States. , 2015 .

[20]  Christian Jacques,et al.  Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. , 2014, The New England journal of medicine.

[21]  P. Wen,et al.  Management of treatment-emergent peripheral neuropathy in multiple myeloma , 2012, Leukemia.

[22]  M. Friedlander,et al.  Impact of oxaliplatin-induced neuropathy: a patient perspective , 2012, Supportive Care in Cancer.

[23]  D. Esseltine,et al.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.

[24]  M. Boccadoro,et al.  Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. , 2010, Blood.

[25]  P. L. Bergsagel,et al.  Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. , 2010, Blood.

[26]  P. Fayers,et al.  What changes in health‐related quality of life matter to multiple myeloma patients? A prospective study * , 2010, European journal of haematology.

[27]  Ethan Basch,et al.  The missing voice of patients in drug-safety reporting. , 2010, The New England journal of medicine.

[28]  O. Bortolami,et al.  Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[30]  R. Fonseca,et al.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. , 2010, The Lancet. Oncology.